Various stakeholders in the pharmaceutical supply chain assign the specialty label to drugs on the basis of a combination of several unrelated factors, including whether a drug treats a rare condition. But the single most common feature of specialty drugs is high cost.
No takes yet. Share an insight, caveat, or question.
Naci et al. (2020) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: